alarm-ringing ambulance angle2 archive arrow-down arrow-left arrow-right arrow-up at-sign baby baby2 bag binoculars book-open book2 bookmark2 bubble calendar-check calendar-empty camera2 cart chart-growth check chevron-down chevron-left chevron-right chevron-up circle-minus circle city clapboard-play clipboard-empty clipboard-text clock clock2 cloud-download cloud-windy cloud clubs cog cross crown cube youtube diamond4 diamonds drop-crossed drop2 earth ellipsis envelope-open envelope exclamation eye-dropper eye facebook file-empty fire flag2 flare foursquare gift glasses google graph hammer-wrench heart-pulse heart home instagram joystick lamp layers lifebuoy link linkedin list lock magic-wand map-marker map medal-empty menu microscope minus moon mustache-glasses paper-plane paperclip papers pen pencil pie-chart pinterest plus-circle plus power pushpin question rain reading receipt recycle reminder sad shield-check smartphone smile soccer spades speed-medium spotlights star-empty star-half star store sun-glasses sun tag telephone thumbs-down thumbs-up tree tumblr twitter user users wheelchair write yelp youtube

Patients with hypotrichosis may experience significant eyelash growth, thickening with bimatoprost, researchers say

Following a previous story, MedPage Today (3/12, Bankhead) reported that, according to clinical trial results presented at the American Academy of Dermatology meeting, “patients with skimpy eyelashes experienced significant growth and thickening when they applied bimatoprost (Latisse), a drug normally used to treat glaucoma.” Researchers from Therapeutics Clinical Research in San Diego, CA, explained that nearly “80 percent of” 278 “patients with hypotrichosis had at least a one-grade improvement in eyelash score after four months of treatment with bimatoprost,” whereas “fewer than 20 percent of patients in a vehicle control group met the one-grade improvement criterion.” The authors theorized that “bimatoprost promotes eyelash development and growth by stimulating the transition from telogen to anagen and prolonging anagen.” Notably, “fewer than four percent of patients encountered adverse events during the trial.” MedPage Today noted that in late 2008, “the FDA approved bimatoprost for eyelash growth.”